Ann: Race Develops Improved IV Formulation of Zantrene, page-15

Two days of outstanding, value-adding announcements. A lot to digest here -

• Those familiar with the Bisantrene OG formula know there were clotting side-effects. Zantrene 2.0 presents this reformulation as a clear solution.
• Budget for manufacture already in place - and handled by a team familiar with our IP. Mitigates risk to a degree.
• Patent clock to be reset until 2043 based on 2023 international patent submission - interested parties can look forward to 18-20 years of commercialization (and holders may see financial benefits if royalties are negotiated).
• Easier to recruit patients due to QOL improvement
• Example reformulation buyout shown at 10x annual sales (RAC have 0 sales under their belt, but this doesn't matter to a prospective buyer who knows this is a pre-market opportunity)
• It expands the potential market size for Zantrene by making it easier to use in clinical practice and target solid tumours.

Another big win today. Now, let's get out from under the radar and showcase this novel treatment far and wide.